NuCana (NASDAQ:NCNA) Announces Quarterly Earnings Results, Beats Estimates By $2.18 EPS

NuCana (NASDAQ:NCNA) posted its earnings results on Thursday. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($2.65) by $2.18, Zacks reports.

NuCana Trading Down 1.0%

Shares of NuCana stock traded down $0.01 during trading hours on Thursday, hitting $0.93. The company had a trading volume of 26,467 shares, compared to its average volume of 27,888. The company’s 50-day moving average is $1.14 and its two-hundred day moving average is $1.66. NuCana has a twelve month low of $0.88 and a twelve month high of $4.55.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of NuCana in a research note on Thursday, October 15th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

About NuCana

NuCana plc is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments. The company uses its ProTide technology to create nucleotide analog medicines designed to improve the delivery and activity of existing chemotherapy agents while addressing mechanisms that can limit treatment effectiveness. NuCana’s development portfolio has included NUC-1031, also known as Acelarin, a ProTide form of gemcitabine evaluated in several solid tumors. The company has also advanced NUC-3373, a ProTide-based fluoropyrimidine designed to deliver the active component of 5-fluorouracil, and NUC-7738, an investigational cancer therapy based on a nucleoside analog.